The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility

Science Signaling

Volumn 7, Issue 339, 2014, Pages

  Kiuchi, Tai ^a,b,c,l   Ortiz Zapater, Elena ^c   Monypenny, James ^a,b,c   Matthews, Daniel R ^a,b,m   Nguyen, Lan K ^d   Barbeau, Jody ^a,b   Coban, Oana ^a,b   Lawler, Katherine ^a,b   Burford, Brian ^c   Rolfe, Daniel J ^e   De Rinaldis, Emanuele ^c   Dafou, Dimitra ^c   Simpson, Michael A ^c   Woodman, Natalie ^c   Pinder, Sarah ^c   Gillett, Cheryl E ^c   Devauges, Viviane ^a,b   Poland, Simon P ^a,b   Fruhwirth, Gilbert ^a,b,n   Marra, Pierfrancesco ^c   Boersma, Ykelien L ^f,o   Plückthun, Andreas ^f   Gullick, William J ^g   Yarden, Yosef ^h   Santis, George ^c   Winn, Martyn ⁱ   Kholodenko, Boris N ^d   Martin Fernandez, Marisa L ^e   Parker, Peter ^b,j   Tutt, Andrew ^c   Ameer Beg, Simon M ^a,b   Ng, Tony ^a,b,c,k   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e Harwell Science and Innovation Campus   (United Kingdom)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g UNIVERSITY OF KENT   (United Kingdom)

^h WEIZMANN INSTITUTE OF SCIENCE   (Israel)

ⁱ DARESBURY LABORATORY   (United Kingdom)

^j IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l TOHOKU UNIVERSITY   (Japan)

^m UNIVERSITY OF QUEENSLAND   (Australia)

ⁿ ST THOMAS HOSPITAL   (United Kingdom)

^o UNIVERSITY OF GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; CYT1 PROTEIN; CYT2 PROTEIN; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HETERODIMER; LIGAND; PROTEIN; PROTEIN VARIANT; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CBL PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; ERBB4 PROTEIN, HUMAN; GRB2 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER CELL MOTILITY; CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CELL STIMULATION; DIMERIZATION; DOWN REGULATION; ENERGY TRANSFER; ENZYME DEGRADATION; EXON; FLUORESCENCE LIFETIME IMAGING MICROSCOPY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LIGAND INDUCED DEGRADATION; MICROSCOPY; MOLECULAR MODEL; PROTEIN INTERACTION; RORSTER RESONANCE ENERGY TRANSFER; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL MOTION; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; FEMALE; GRB2 ADAPTOR PROTEIN; HUMANS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-4;

EID: 84906829733     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005157     Document Type: Article

References (88)

1. A. Citri, Y. Yarden, EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 7, 505-516 (2006).
2. Y. Yarden, M. X. Sliwkowski, Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001).
3. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. P. Dong, J. Baselga, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-2246 (2003).
4. E. E. Cohen, F. Rosen, W. M. Stadler, W. Recant, K. Stenson, D. Huo, E. E. Vokes, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21, 1980-1987 (2003).
5. L. B. Saltz, N. J. Meropol, P. J. Loehrer Sr., M. N. Needle, J. Kopit, R. J. Mayer, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004).
6. R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, P. Bonomi, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22, 3238-3247 (2004).
7. A. F. Leary, S. Drury, S. Detre, S. Pancholi, A. E. Lykkesfeldt, L. A. Martin, M. Dowsett, S. R. D. Johnston, Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin. Cancer Res. 16, 1486-1497 (2010).
8. C. A. Hudis, L. Gianni, Triple-negative breast cancer: An unmet medical need. Oncologist 16 (Suppl. 1), 1-11 (2011).
9. A. Evans, A. F. Leary, S. R. Johnston, R. A. Hern, J.M. Bliss, M. H. Hills, C. Harper-Wynne, N. Bundred, G. Coombes, R. Sahoo, S. Detre, I. E. Smith, M. Dowsett, Lapatinib has antiproliferative effects in both HER2 positive (+) and HER2 negative (-) breast cancer (BC): Results from the MAPLE short-term pre-surgical trial (CRUK E/06/039). Cancer Res. 72 (Suppl. 1), abstract LB-222 (2012).
10. I. A. Mayer, C. L. Arteaga, Does lapatinib work against HER2-negative breast cancers? Clin. Cancer Res. 16, 1355-1357 (2010).
11. K. Zhang, J. Sun, N. Liu, D. Wen, D. Chang, A. Thomason, S. K. Yoshinaga, Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271, 3884-3890 (1996).
12. B. D. Cohen, P. A. Kiener, J. M. Green, L. Foy, H. P. Fell, K. Zhang, The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J. Biol. Chem. 271, 30897-30903 (1996).
13. D. J. Riese II, D. F. Stern, Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20, 41-48 (1998).
14. M. A. Alaoui-Jamali, D. J. Song, N. Benlimame, L. Yen, X. Deng, M. Hernandez-Perez, T. Wang, Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res. 63, 3764-3774 (2003).
15. S. Sigismund, E. Argenzio, D. Tosoni, E. Cavallaro, S. Polo, P. P. Di Fiore, Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 15, 209-219 (2008).
16. S. Sigismund, T. Woelk, C. Puri, E. Maspero, C. Tacchetti, P. Transidico, P. P. Di Fiore, S. Polo, Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. U.S.A. 102, 2760-2765 (2005).
17. S. Sigismund, V. Algisi, G. Nappo, A. Conte, R. Pascolutti, A. Cuomo, T. Bonaldi, E. Argenzio, L. G. Verhoef, E. Maspero, F. Bianchi, F. Capuani, A. Ciliberto, S. Polo, P. P. Di Fiore, Threshold-controlled ubiquitination of the EGFR directs receptor fate. EMBO J. 32, 2140 -2157 (2013).
18. G. Levkowitz, H. Waterman, S. A. Ettenberg, M. Katz, A. Y. Tsygankov, I. Alroy, S. Lavi, K. Iwai, Y. Reiss, A. Ciechanover, S. Lipkowitz, Y. Yarden, Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4, 1029-1040 (1999).
19. J. J. Tao, P. Castel, N. Radosevic-Robin, M. Elkabets, N. Auricchio, N. Aceto, G. Weitsman, P. Barber, B. Vojnovic, H. Ellis, N. Morse, N. T. Viola-Villegas, A. Bosch, D. Juric, S. Hazra, S. Singh, P. Kim, A. Bergamaschi, S. Maheswaran, T. Ng, F. Penault-Llorca, J. S. Lewis, L. A. Carey, C. M. Perou, J. Baselga, M. Scaltriti, Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci. Signal. 7, ra29 (2014).
20. C. M. Perou, T. Sørlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lønning, A. L. Børresen-Dale, P. O. Brown, D. Botstein, Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
21. M. Sundvall, K. Iljin, S. Kilpinen, H. Sara, O. P. Kallioniemi, K. Elenius, Role of ErbB4 in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 259-268 (2008).
22. K. Elenius, C. J. Choi, S. Paul, E. Santiestevan, E. Nishi, M. Klagsbrun, Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18, 2607-2615 (1999).
23. V. Kainulainen, M. Sundvall, J. A. Määttä, E. Santiestevan, M. Klagsbrun, K. Elenius, A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J. Biol. Chem. 275, 8641-8649 (2000).
24. J. Omerovic, L. Santangelo, E. M. Puggioni, J. Marrocco, C. Dall 'Armi, C. Palumbo, F. Belleudi, L. Di Marcotullio, L. Frati, M. R. Torrisi, G. Cesareni, A. Gulino, M. Alimandi, The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J. 21, 2849-2862 (2007).
25. M. Sundvall, A. Korhonen, I. Paatero, E. Gaudio, G. Melino, C. M. Croce, R. I. Aqeilan, K. Elenius, Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc. Natl. Acad. Sci. U.S.A. 105, 4162-4167 (2008).
26. F. Y. Feng, S. Varambally, S. A. Tomlins, P. Y. Chun, C. A. Lopez, X. Li, M. A. Davis, A. M. Chinnaiyan, T. S. Lawrence, M. K. Nyati, Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 26, 3431-3439 (2007).
27. F. Zeng, J. Xu, R. C. Harris, Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J. 23, 1935-1945 (2009).
28. T. T. Junttila, M. Sundvall, M. Lundin, J. Lundin, M. Tanner, P. Härkönen, H. Joensuu, J. Isola, K. Elenius, Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 65, 1384-1393 (2005).
29. N. Anilkumar, M. Parsons, R. Monk, T. Ng, J. C. Adams, Interaction of fascin and protein kinase Cα: A novel intersection in cell adhesion and motility. EMBO J. 22, 5390-5402 (2003).
30. J. W. Legg, C. A. Lewis, M. Parsons, T. Ng, C. M. Isacke, A novel PKC-regulated mechanism controls CD44-ezrin association and directional cell motility. Nat. Cell Biol. 4, 399-407 (2002).
31. T. Ng, M. Parsons, W. E. Hughes, J. Monypenny, D. Zicha, A. Gautreau, M. Arpin, S. Gschmeissner, P. J. Verveer, P. I. Bastiaens, P. J. Parker, Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J. 20, 2723-2741 (2001).
32. T. Ng, A. Squire, G. Hansra, F. Bornancin, C. Prevostel, A. Hanby, W. Harris, D. Barnes, S. Schmidt, H. Mellor, P. I. Bastiaens, P. J. Parker, Imaging protein kinase Cα activation in cells. Science 283, 2085-2089 (1999).
33. M. Parsons, M. D. Keppler, A. Kline, A. Messent, M. J. Humphries, R. Gilchrist, I. R. Hart, C. Quittau-Prevostel, W. E. Hughes, P. J. Parker, T. Ng, Site-directed perturbation of protein kinase C-integrin interaction blocks carcinoma cell chemotaxis. Mol. Cell. Biol. 22, 5897-5911 (2002).
34. M. Parsons, J. Monypenny, S. M. Ameer-Beg, T. H. Millard, L. M. Machesky, M. Peter, M. D. Keppler, G. Schiavo, R. Watson, J. Chernoff, D. Zicha, B. Vojnovic, T. Ng, Spatially distinct binding of Cdc42 to PAK1 and N-WASP in breast carcinoma cells. Mol. Cell. Biol. 25, 1680-1695 (2005).
35. S. Prag, M. Parsons, M. D. Keppler, S. M. Ameer-Beg, P. Barber, J. Hunt, A. J. Beavil, R. Calvert, M. Arpin, B. Vojnovic, T. Ng, Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42. Mol. Biol. Cell 18, 2935-2948 (2007).
36. G. Tarcic, S. K. Boguslavsky, J. Wakim, T. Kiuchi, A. Liu, F. Reinitz, D. Nathanson, T. Takahashi, P. S. Mischel, T. Ng, Y. Yarden, An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr. Biol. 19, 1788-1798 (2009).
37. E. M. Bublil, G. Pines, G. Patel, G. Fruhwirth, T. Ng, Y. Yarden, Kinase-mediated quasi-dimers of EGFR. FASEB J. 24, 4744-4755 (2010).
38. R. Iwamoto, E. Mekada, Heparin-binding EGF-like growth factor: A juxtacrine growth factor. Cytokine Growth Factor Rev. 11, 335-344 (2000).
39. C. Y. Ni, M. P. Murphy, T. E. Golde, G. Carpenter, γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294, 2179-2181 (2001).
40. M. Hatakeyama, N. Yumoto, X. Yu, M. Shirouzu, S. Yokoyama, A. Konagaya, Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase. Oncogene 23, 5023-5031 (2004).
41. Y. Li, Z. Zhou, M. Alimandi, C. Chen, WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 28, 2948-2958 (2009).
42. D. Steiner, P. Forrer, A. Plückthun, Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J. Mol. Biol. 382, 1211- 1227 (2008).
43. A. Sorkin, L. K. Goh, Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 314, 3093-3106 (2008).
44. L. Duan, S. M. Raja, G. Chen, S. Virmani, S. H. Williams, R. J. Clubb, C. Mukhopadhyay, M. A. Rainey, G. Ying, M. Dimri, J. Chen, A. L. Reddi, M. Naramura, V. Band, H. Band, Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J. Biol. Chem. 286, 620-633 (2011).
45. D. Zicha, G. A. Dunn, A. F. Brown, A new direct-viewing chemotaxis chamber. J. Cell Sci. 99, 769-775 (1991).
46. E. F. Foxman, E. J. Kunkel, E. C. Butcher, Integrating conflicting chemotactic signals. The role of memory in leukocyte navigation. J. Cell Biol. 147, 577-588 (1999).
47. X. Zhang, J. Gureasko, K. Shen, P. A. Cole, J. Kuriyan, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 (2006).
48. X. Zhang, K. A. Pickin, R. Bose, N. Jura, P. A. Cole, J. Kuriyan, Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450, 741-744 (2007).
49. H. Zhang, A. Berezov, Q. Wang, G. Zhang, J. Drebin, R. Murali, M. I. Greene, ErbB receptors: From oncogenes to targeted cancer therapies. J. Clin. Invest. 117, 2051-2058 (2007).
50. S. T. Low-Nam, K. A. Lidke, P. J. Cutler, R. C. Roovers, P. M. van Bergen en Henegouwen, B. S. Wilson, D. S. Lidke, ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding. Nat. Struct. Mol. Biol. 18, 1244-1249 (2011).
51. D. Graus-Porta, R. R. Beerli, J. M. Daly, N. E. Hynes, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (1997).
52. K. Aertgeerts, R. Skene, J. Yano, B. C. Sang, H. Zou, G. Snell, A. Jennings, K. Iwamoto, N. Habuka, A. Hirokawa, T. Ishikawa, T. Tanaka, H. Miki, Y. Ohta, S. Sogabe, Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J. Biol. Chem. 286, 18756-18765 (2011).
53. T. Y. Chou, C. H. Chiu, L. H. Li, C. Y. Hsiao, C. Y. Tzen, K. T. Chang, Y. M. Chen, R. P. Perng, S. F. Tsai, C. M. Tsai, Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 3750-3757 (2005).
54. P. R. Barber, S. M. Ameer-Beg, J. Gilbey, L. M. Carlin, M. Keppler, T. C. Ng, B. Vojnovic, Multiphoton time-domain fluorescence lifetime imaging microscopy: Practical application to protein-protein interactions using global analysis. J. R. Soc. Interface 6, S93-S105 (2009).
55. K. Makrogianneli, L. M. Carlin, M. D. Keppler, D. R. Matthews, E. Ofo, A. Coolen, S. M. Ameer-Beg, P. R. Barber, B. Vojnovic, T. Ng, Integrating receptor signal inputs that influence small Rho GTPase activation dynamics at the immunological synapse. Mol. Cell. Biol. 29, 2997-3006 (2009).
56. C. P. Mill, M. D. Zordan, S. M. Rothenberg, J. Settleman, J. F. Leary, D. J. Riese II, ErbB2 is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast. Cancer Genes Cancer 2, 792-804 (2011).
57. J. A. Määttä, M. Sundvall, T. T. Junttila, L. Peri, V. J. Laine, J. Isola, M. Egeblad, K. Elenius, Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol. Biol. Cell 17, 67-79 (2006).
58. H. S. Wiley, S. Y. Shvartsman, D. A. Lauffenburger, Computational modeling of the EGF-receptor system: A paradigm for systems biology. Trends Cell Biol. 13, 43-50 (2003).
59. B. S. Hendriks, J. Cook, J. M. Burke, J. M. Beusmans, D. A. Lauffenburger, D. de Graaf, Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity. Syst. Biol. 153, 22-33 (2006).
60. B. N. Kholodenko, O. V. Demin, G. Moehren, J. B. Hoek, Quantification of short term signaling by the epidermal growth factor receptor. J. Biol. Chem. 274, 30169-30181 (1999).
61. H. Shankaran, H. S. Wiley, H. Resat, Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys. J. 90, 3993-4009 (2006).
62. M. F. Ciaccio, J. P. Wagner, C. P. Chuu, D. A. Lauffenburger, R. B. Jones, Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat. Methods 7, 148-155 (2010).
63. A. Z. Lai, J. V. Abella, M. Park, Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19, 542-551 (2009).
64. L. M. Grøvdal, E. Stang, A. Sorkin, I. H. Madshus, Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp. Cell Res. 300, 388-395 (2004).
65. K. J. Wilson, C. Mill, S. Lambert, J. Buchman, T. R. Wilson, V. Hernandez-Gordillo, R. M. Gallo, L. M. Ades, J. Settleman, D. J. Riese II, EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 30, 107-116 (2012).
66. V. Pawlowski, F. Révillion, M. Hebbar, L. Hornez, J. P. Peyrat, Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6, 4217-4225 (2000).
67. C. J. Witton, J. R. Reeves, J. J. Going, T. G. Cooke, J. M. Bartlett, Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200, 290-297 (2003).
68. A. J. Lodge, J. J. Anderson, W. J. Gullick, B. Haugk, R. C. F. Leonard, B. Angus, Type 1 growth factor receptor expression in node positive breast cancer: Adverse prognostic significance of c-erbB-4. J. Clin. Pathol. 56, 300-304 (2003).
69. M. Bailly, J. Wyckoff, B. Bouzahzah, R. Hammerman, V. Sylvestre, M. Cammer, R. Pestell, J. E. Segall, Epidermal growth factor receptor distribution during chemotactic responses. Mol. Biol. Cell 11, 3873-3883 (2000).
70. M. Parsons, T. Ng, Intracellular coupling of adhesion receptors: Molecular proximity measurements. Methods Cell Biol. 69, 261-278 (2002).
71. Z. N. Zhou, V. P. Sharma, B. T. Beaty, M. Roh-Johnson, E. A. Peterson, N. Van Rooijen, P. A. Kenny, H. S. Wiley, J. S. Condeelis, J. E. Segall, Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. Oncogene 33, 3784-3793 (2014).
72. D. J. Rolfe, C. I. McLachlan, M. Hirsch, S. R. Needham, C. J. Tynan, S. E. Webb, M. L. Martin-Fernandez, M. P. Hobson, Automated multidimensional single molecule fluorescence microscopy feature detection and tracking. Eur. Biophys. J. 40, 1167-1186 (2011).
73. S. E. Webb, S. K. Roberts, S. R. Needham, C. J. Tynan, D. J. Rolfe, M. D. Winn, D. T. Clarke, R. Barraclough, M. L. Martin-Fernandez, Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity epidermal growth factor receptors in A431 cells. Biophys. J. 94, 803-819 (2008).
74. H. P. Lu, L. Xun, X. S. Xie, Single-molecule enzymatic dynamics. Science 282, 1877-1882 (1998).
75. F. Festy, S. M. Ameer-Beg, T. Ng, K. Suhling, Imaging proteins in vivo using fluorescence lifetime microscopy. Mol. Biosyst. 3, 381-391 (2007).
76. J. Monypenny, D. Zicha, C. Higashida, F. Oceguera-Yanez, S. Narumiya, N. Watanabe, Cdc42 and Rac family GTPases regulate mode and speed but not direction of primary fibroblast migration during platelet-derived growth factor-dependent chemotaxis. Mol. Cell. Biol. 29, 2730-2747 (2009).
77. S. E. Webb, J. W. Pollard, G. E. Jones, Direct observation and quantification of macrophage chemoattraction to the growth factor CSF-1. J. Cell Sci. 109 (Pt. 4), 793-803 (1996).
78. D. Zicha, G. A. Dunn, Are growth factors chemotactic agents? Exp. Cell Res. 221, 526-529 (1995).
79. H. Zhang, L. Vutskits, V. Calaora, P. Durbec, J. Z. Kiss, A role for the polysialic acid-neural cell adhesion molecule in PDGF-induced chemotaxis of oligodendrocyte precursor cells. J. Cell Sci. 117, 93-103 (2004).
80. E. de Rinaldis, P. Gazinska, A. Mera, Z. Modrusan, G. M. Fedorowicz, B. Burford, C. Gillett, P. Marra, A. Grigoriadis, D. Dornan, L. Holmberg, S. Pinder, A. Tutt, Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics 14, 643 (2013).
81. E. Purdom, K. M. Simpson, M. D. Robinson, J. G. Conboy, A. V. Lapuk, T. P. Speed, FIRMA: A method for detection of alternative splicing from exon array data. Bioinformatics 24, 1707-1714 (2008).
82. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
83. W. Humphrey, A. Dalke, K. Schulten, VMD: Visual molecular dynamics. J. Mol. Graphics 14, 33-38, 27-28 (1996).
84. S. McNicholas, E. Potterton, K. S. Wilson, M. E. Noble, Presenting your structures: The CCP4mg molecular-graphics software. Acta Crystallogr. D Biol. Crystallogr. 67, 386-394 (2011).
85. H. S. Wiley, J. J. Herbst, B. J. Walsh, D. A. Lauffenburger, M. G. Rosenfeld, G. N. Gill, The role of tyrosine kinase activity in endocytosis, compartmentation, and downregulation of the epidermal growth factor receptor. J. Biol. Chem. 266, 11083-11094 (1991).
86. A. Tomas, C. E. Futter, E. R. Eden, EGF receptor trafficking: Consequences for signaling and cancer. Trends Cell Biol. 24, 26-34 (2014).
87. L. K. Nguyen, M. A. Cavadas, C. C. Scholz, S. F. Fitzpatrick, U. Bruning, E. P. Cummins, M. M. Tambuwala, M. C. Manresa, B. N. Kholodenko, C. T. Taylor, A. Cheong, A dynamic model of the hypoxia-inducible factor 1α (HIF-1α) network. J. Cell Sci. 126, 1454-1463 (2013).
88. M. R. Birtwistle, M. Hatakeyama, N. Yumoto, B. A. Ogunnaike, J. B. Hoek, B. N. Kholodenko, Ligand-dependent responses of the ErbB signaling network: Experimental and modeling analyses. Mol. Syst. Biol. 3, 144 (2007).